Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating with a Price Target of $14.00 from CB Capital Partners

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12 Month Price Target of $16.00 from D. Boral Capital

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

Estrella Immunopharma Doses First Patient in Phase I/II Trial of EB103 in Advanced B-cell Non-Hodgkin’s Lymphomas

Estrella Immunopharma Announces $1 Million Share Repurchase Authorization

Estrella Immunopharma Announces Publication in Blood Demonstrating ARTEMIS T Cell’s Potential in Addressing Acute Myeloid Leukemia (AML)

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination